No Journal Sample Size Revascularization Risk Factor Patients Long Term Long Term Long Term Long Term

Long Term Long Term Long Term Long Term Late MACE
Author, and Study Method Syndrome Mortality Revascularization Myocardial Stroke
Country, Design Induced Infarction
and Year
1 Naganuma 856 PCI to CABG Hypertension, ULMCA 46 patients (9.5%) : 45 patients (9.3%). 20 patients 8 patients 97 patients
et al, 2014 Prospective dyslipidemia, smoker, 26 cardiac death HR: 1.94, 95% CI: (3.9%). HR: 1.38, (1.7%). HR: (20.1%). HR: 1.40,
Italy study-DELTA IDDM, NIDDM, CKD, (5.4%) + 20 1.03 to 3.64; p : 0.039 95% CI: 0.82 to 1.25, 95% CI: 95% CI: 0.93 to
multinational noncardiac death 2.31; p : 0.220 0.78 to 2.01; p : 2.10; p : 0.104
registry (4.1%). HR: 1.31, 0.350
95% CI: 0.74 to
2.32; p : 0.348
29 patients (7.7%) : 14 patients (3.7%). 18 patients 8 patients 58 patients
15 cardiac death HR: 2.00, 95% CI: (4.8%). HR: 1.38, (2.1%). HR: (15.5%). HR: 1.40,
(4.0%) + 14 0.90 to 4.45; p : 0.090 95% CI: 0.82 to 1.25, 95% CI: 95% CI: 0.93 to
noncardiac death 2.31; p : 0.220 0.78 to 2.01; p : 2.10; p : 0.104
(3.7%). HR: 1.31, 0.350
95% CI: 0.74 to
2.32; p : 0.348
2 Jeong et al, 899 PCI DES to CABG Diabetes mellitus, LMCA 0-8 years: HR 0-8 years: incidence 0-8 years: 0-8 years: 0-8 years:
2013 Retrospective hypertension, smoking, 1.435, CI :0.62– on PCI 10.1%, on incidence on PCI incidence on incidence on PCI
South Korea study-registry previous PCI, CKD, 3.31, p value: 0.396 OPCAB 1.3%, HR 4.3%, on OPCAB PCI 1.7%, on 24.1% (83
dyslipidemia, previous 5.508, CI :1.87–16.22, 1.8%HR 4.730, OPCAB 1.3%, patients) OPCAB
MI, cerebrovascular p value: 0.002 CI :0.99–22.63, p HR 3.010, 13.1% (72
disease, PVD value: 0.049 CI :0.33–27.44, patients), HR
p value: 0.329 1.249, CI :2.165–
8.121, p value: <
0.001
3 Buszman et 105 PCI to CABG Hypertension, ULMCA 21.6%, p value:0.41 repeated 8.7% (HR: 1.14; stroke and TIA 52.2%, p
al, 2016 Prospective hypercholesterolemia, patients revascularization 95% CI: 0.30 to 4.3% (HR: 2.85; value:0.42
Poland observational previous MI, DM with at least 26.1% (p value: 0.39), 4.25; p 1⁄4 0.83) 95% CI: 0.40 to
study-LE 50% re PCI 19.6% (p 20.4; p 1⁄4 0.29)
MANS Trial diameter value: 0.81) (HR:
stenosis, 1.34; 95% CI: 0.61 to
with or 2.95; p : 0.46)
without
30.2%, p value:0.41 repeated 10.4% (HR: 1.14; stroke and TIA 62.5%, p
multivessel
revascularization 95% CI: 0.30 to 6.3% (HR: 2.85; value:0.42
coronary
31.3% (p value: 0.39), 4.25; p 1⁄4 0.83) 95% CI: 0.40 to
artery
re PCI 27.1% (p 20.4; p 1⁄4 0.29)
disease
value: 0.81) (HR:
1.34; 95% CI: 0.61 to
2.95; p : 0.46)
4 Papadopoulo 140 Second-generation Smoker, CAD PCI 4 patients PCI 3 patients (4.3%), Angina : PCI 7 NA NA
s et al, 2017 Prospective DES PCI to CABG Hyperlipidemia, (MVD (5.7%), CABG 8 CABG 6 patients patients (10%),
Cyprus observational Hypertension, Diabetes and/or (11.4%), p value: (8.6%), p value: 0.135 CABG 13 patients
study mellitus, Family ULMCAD) 0.115 (18.6%), p value:
history, Overweight, 0.153. MI : PCI 0
CAD, EF<30%, CKD patients (0%),
CABG 3 patients
(4.3%), p value: -
5 Gallo et al, 4595 PCI DES to CABG DM  ULMCA 30 days OR = 0.65 30 days OR = 0.56 30 days OR = 30 days OR = 30 days OR = 0.66
2020 RCT (95% CI 0.30, 1.39), (95% CI, 0.29, 1.08) 0.75 (95% CI, 0.39 (95% CI, (95% CI, 0.49,
America p=0.27 ; 1 year OR p= 0.08 ; 1 year OR = 0.53, 1.06) p= 0.16, 0.98) p = 0.90) p = 0.009; 1
= 0.80 (95% CI 1.74 (95% CI, 1.35, 0.11 ; 1 year OR = 0.05, 1 year OR year 0.78 (95% CI,
0.57, 1.12), p=0.20 ; 2.23) p<0.001 ; 5 0.90 (95% CI, = 0.39 (95% CI, 0.63, 0.96) p =
5 years OR = 1.13 years OR = 1.89 (95% 0.68, 1.18) p= 0.21, 0.73), p = 0.02; 5 years OR =
(95% CI 0.93, 1.38), CI, 1.58, 2.26) 0.45; 5 years OR 0.003; 5 years 1.22 (95% CI,
p=0.21 p<0.001 = 1.43 (95% CI, OR = 0.88 (95% 1.05, 1.42) p =
1.13, 1.79) p= CI, 0.61, 1.28), 0.009
0.003 p = 0.51
6 Anand et al, 117 PCI to CABG DM, hypertension,  ULMCA 30 days 1 (2.7%) vs 30 days 0vs 0 ; 12 30 days 0 vs 0 ; 30 days 0 vs 2 30 days 1 (2.7%)
2016 Retrospective dyslipidemia, smoker, 2 (2.5%) OR = 1.08 months 2 (5.41%) vs 12 months 1 (2.5%) OR = vs 4 (5%) OR =
India observational CHF NYHA III-IV, (0.09-12.30) p = 0 OR = 10.73 (2.70%) vs 0 OR 0.43 (0.02-9.17) 0.54 (95%CI 0.06-
study- ACS 0.95 ; 12 months 2 (95%CI 0.50-229.15) = 6.44 (95%CI P = 0.59 ; 12 5.01) p = 0.59 ; 12
EXCEL trial (5.41%) vs 3 p = 0.13 ; 30 months 0.26 - 161.83) p = months 0 vs 2 months 3 (8.11%)
(3.75%) OR = 1.44 3 (8.11%) vs 0 OR = 0.26 ; 30 months (2.5%) OR = vs 5 (6.25%) OR =
(0.23 - 8.99) p = 15.03 (95%CI 0.76- 1 (2.70%) vs 0 0.43 (0.02-9.17) 1.29 (95%CI 0.29-
0.69 ; 30 months 3 298.4) p = 0.08 OR = 6.44 P = 0.59 ; 30 5.72) p = 0.73 ; 30
(8.11%) vs 3 (95%CI 0.26 - months 0 vs 2 months 5 (13.51%)
(3.75%) OR = 2.16 161.83) p = 0.26 (2.5%) OR = vs 5 (6.25%) OR =
(0.42-11.22) p = 0.43 (0.02-9.17) 2.16 (95%CI 0.59-
0.36 P = 0.59 7.93) p = 0.24
7 Hsin-Ru Li 99 PCI DES to CABG Hypertension, Smoking, ULMCA, 30 days 2 (4.3%) vs 15 (32.6%) VS 5 7 (15.2%) VS 4 1 (2.2%) VS 3 30 days 2 (4.3%)
et al, 2017 Retrospective dyslipidemia Diabetic 4 (7.5%) P; 0.68 ; (9.4%) P < 0.01 (7.5%) P : 0.23 (5.7%) P : 0.62 vs 4 (7.5%) P :
Taiwan observational nephropathy long term 21 0.68 ; long term 31
study- (45.7%) vs 31 (67.4%) VS 34
SYNTAX (58.5%) P : 0.20 (64.2%) P : 0.73
trial
8 Sotomi et al, 3280 PCI DES to CABG Hypertension, dm,  NA 1611 - 1837 days; HR 2.03 (1.67 - 2.46) HR 2.16 (1.54- hr 0.68 (0.43- hr 1.45 (1.26-1.67)
2017 RCT smoker, dyslipidemia, HR 1.17 (0.82 - p <0.00001 3.02) p < 0.00001 1.07) p : 0.10 p <0.00001
UK copd, peripheral 1.67) p : 0.40
vascular disease, silent
myocardial ischemia,
angina

9 Hyun et al, 2240 PCI (DES and Hypertension, Diabetes, Silent 0-5 years: HR 1.19 0-5 years: HR 4.76 0-5 years: HR 0-5 years: HR NA
2020 Retrospective BMS) to CABG Hyperlipidemia, Ischemia, (0.79–1.82) p value: (2.86–7.69) p value: 1.11 (0.76–1.64) p 1.11 (0.76–1.64)
Korea study-MAIN Smoking, Stable 0.42 <0.001 value: 0.59 p value: 0.59
COMPARE Cerebrovascular Angina,
registry disease, Chronic Kidney Unstable
Disease Angina, >5 years: HR 1.44 >5 years: HR 2.33 >5 years: 1.52 >5 years: 1.52 NA
NSTEMI (1.06–1.96) p value: (1.09–4.98) p value: (1.13–2.05) p (1.13–2.05) p
0.02 0.03 value: 0.006 value: 0.006
10 Zheng et al, 4046 PCI (DES) to Hypertension, Silent 3 years: HR 1.71 3 years: HR 4.91 3 years: HR 2.00 3 years: HR 3 years: HR 2.44
2016 Prospective CABG Hyperlipidemia, Ischemia, (1.32–2.21) p value: (3.91–6.16) p value: (1.61–2.50) p 0.18 (0.13–0.26) (1.75–3.42) p
China study-registry Diabetes Mellitus, Stable <0.001 <0.001 value: <0.001 p value: <0.001 value: <0.001
Smoking, COPD, Angina,
Family History of CAD, Unstable
BMI, Creatine Angina

11 Yu et al, 922 PCI (DES) to Diabetes Mellitus, NSTEMI, Median 7.1 years: Median 7.1 years: HR Median 7.1 years: Median 7.1 Median 7.1 years:
2016 Prospective CABG Smoking, Hypertension, STEMI, HR 0.647 (0.439– 2.256 (1.633–3.115) p HR 1.407 (0.836– years: HR 0.298 HR 1.204 (0.951–
China Observational Family History, Stable 0.954) p value: value: <0.001 2.366) p value: (0.153–0.581) p 1.523) p value:
Study Dyslipidemia Angina, 0.027 0.196 value: <0.001 0.122
Unstable
Angina,
Silent
Ischemia
12 Ahn et al, 600 PCI to CABG NA NA 5 years: HR 0.73 5 years: HR 1.86 5 years: HR 1.20 5 years: HR 5 years: HR 1.27
2015 Prospective (0.39–1.37) p value: (1.09–3.17) p value: (0.37–3.93) p 0.99 (0.14–7.02) (0.84–1.90) p
China Observational 0.32 0.020 value: 0.76 p value: 0.99 value: 0.26
Study

13 Morrice et 1800 PCI to CABG NA NA 5 years: HR 0.88 5 years: HR 4.16 5 years: HR 1.67 5 years: HR 5 years: HR 1.23
al, 2014 Prospective [0.58, 1.32] p value: [1.71, 10.10] p value: [0.91, 3.10] p 0.33 [0.12, 0.92] [0.95, 1.59] p
USA Observational 0.53 <0.001 value: 0.10 p value: 0.03 value: 0.12
Study

14 Makikallio 1202 PCI to CABG BMI, Diabetes Mellitus, Stable 5 years: HR 1·08 5 years: HR 5 years: HR 2·87 5 years: HR 5 years: HR 1·51
et al, 2016 Prospective Hypertension, Active Angina (0·67–1·74) p 1·50(1·04–2·17) p (1·40–5·89) p 1·93 (0·17– (1·13–2·00) p
Multicenter Observational Smoking, Pectoris, value: 0·84 value: 0·0304 value: 0·0040 21·26) p value: value: 0·0044
(Latvia, Study- Acute 0·59
Estonia, NOBLE trial Coronary
Lithuania, Syndrome
Germany,
Norway,
Sweden,
Finland, the
UK, and
Denmark)

15 Stone et al, 1905 PCI with Diabetes, Hypertension, STEMI, 30 days: HR 0.90 30 days: HR 0.54 30 days: HR 0.63 30 days: HR NA
2016 Prospective everolimus-eluting Hyperlipidemia, NSTEMI, (0.37–2.22) p value: (0.21–1.35) p value: (0.42–0.95) p 0.50 (0.19–1.33)
UK study stents to CABG Current Smoker, BMI, Unstable 0.82 0.18 value: 0.02 p value: 0.15
Thrombocytopenia, Angina,
Anemia Stable 3 years: HR 1.34 3 years: HR 1.72 3 years: HR 0.93 3 years: HR NA
Angina, (0.94–1.91) p value: (1.27–2.33) p value: (0.67–1.28) p 0.77 (0.43–1.37)
Silent 0.11 <0.001 value: 0.64 p value: 0.37
Ischemia
16 Ono et al, 1800 PCI to CABG >70 years, BMI, Silent 5 years: elderly HR 5 years: elderly HR 5 years: elderly 5 years: elderly 5 years: elderly HR
2021 Prospective Diabetes Mellitus, Ischemia, 1.08 (0.75–1.55) p 2.11 (1.35–3.31) p HR 2.08 (1.10– HR 0.78 (0.35– 1.18 (0.90–1.56) p
Netherlands study- Metabolic Syndrome, Stable value: 0.678; non value: 0.001; non 3.91) p value: 1.73) p value: value: 0.233; non
SYNTAX Hypertension, Angina, elderly HR 1.46 elderly HR 2.04 0.024; non elderly 0.534; non elderly HR 1.69
 Trials Dyslipidemia, Current Unstable (0.98–2.18) p value: (1.57–2.67) p value: HR 2.76 (1.63– elderly HR 0.48 (1.36–2.10) p
Smoking, Previous MI, Angina 0.064 <0.001 4.66) p value: (0.22–1.08) p value: <0.001
Cerebrovascular <0.001 value: 0.075
Disease, Peripheral 10 years: elderly NA NA NA NA
Vascular Disease, HR 1.08 (0.84–
COPD, CKD, CHF, 1.40) p value:
Creatine Clearance, 0.530; non elderly
LVEF HR 1.30 (1.00–
1.69) p value: 0.052
17 Park et al, 3488 PCI to CABG BMI, Hypertension, Silent 5 years Normal LV 5 years Normal LV 5 years Normal 5 years Normal NA
2020 Prospective Diabetes Mellitus, Ischemia, HR: 0.79 (0.591.07) HR: 3.38 (2.294.99) p LV HR:1.26 LV HR: 0.59
Korea study-ongoing Hyperlipidemia, Stable p value: 0.12 value: <0.001 (0.592.69) p (0.331.07) p
IRIS MAIN Smoking, Previous MI, Angina, value: 0.56 value: 0.08
Registry Chronic Lung Disease, Unstable 5 years Mild LV 5 years Mild LV HR: 5 years Mild LV 5 years Mild LV NA
Chronic Renal Failure, Angina, HR: 1.00 (0.601.66) 5.44 (1.8615.93) p NA HR: 0.36
Dyalisis, CHF NTEMI, p value: 0.99 value: 0.002 (0.091.40) p
STEMI value: 0.14
5 years Moderate 5 years Moderate LV 5 years Moderate 5 years NA
LV HR: 1.35 HR: 4.84 (1.2818.32) LV HR: 3.78 Moderate LV
(0.772.38) p value: p value: 0.02 (0.3442.1) p HR: 1.02
0.30 value: 0.28 (0.293.63) p
value: 0.97
5 years Severe LV 5 years Severe LV 5 years Severe LV 5 years Severe NA
HR: 1.36 (0.822.27) HR: 1.86 (0.625.62) p HR: 2.92 LV HR: 1.41
p value: 0.23 value: 0.27 (0.4817.8) p (0.395.12) p
value: 0.25 value: 0.60
18 Park et al, 5349 PCI to CABG BMI, Hypertension, Silent 5 years Female HR: 5 years Female HR: 5 years Female 5 years Female NA
2021 Prospective Diabetes Mellitus, Ischemia, 1.12 (0.67−1.87) p 5.75 (2.94−11.26) p Unadjusted HR: Unadjusted HR:
Korea study-ongoing Hyperlipidemia, Stable value: 0.661 value: <0.001 1.56 (0.49−4.91) 0.59
IRIS MAIN Smoking, Previous Angina, p value: 0.450 (0.24−1.47) p
Registry myocardial infarction, Unstable value: 0.259
Previous percutaneous Angina, 5 years Male HR: 5 years Male HR: 5 years Male 5 years Male NA
coronary intervention, NTEMI, 0.89 (0.69−1.13) p 4.90 (3.31−7.27) p Unadjusted HR: Unadjusted HR:
Previous STEMI value: 0.326 value: <0.001 1.52 (0.75−3.07) 0.58
cerebrovascular p value: 0.245 (0.36−0.91) p
accident, Peripheral value: 0.019
artery disease, Chronic
10 years Female 10 years Female HR: 10 years Female 10 years Female NA
lung disease, Chronic
HR: 1.21 6.30 (3.23−12.29) p Unadjusted HR: Unadjusted HR:
renal failure, Dialysis,
(0.77−1.90) p value: value: <0.001 1.31 (0.48−3.53) 0.50
Congestive heart
0.415 p. value: 0.599 (0.23−1.12) p
failure, Atrial
value: 0.094
fibrillation, Acute
coronary syndrome 10 years Male HR: 10 years Male HR: 10 years Male 10 years Male NA
0.94 (0.75−1.16) p 5.05 (3.48−7.32) p Unadjusted HR: Unadjusted HR:
value: 0.542 value: <0.001 1.58 (0.82−3.06) 0.60
p value: 0.171 (0.39−0.94) p
value: 0.025